Skip to Content

Mitoxantrone Pregnancy and Breastfeeding Warnings

Mitoxantrone is also known as: Novantrone

Mitoxantrone Pregnancy Warnings

Mitoxantrone has been assigned to pregnancy category D by the FDA. Animal data have revealed evidence of fetotoxicity (low fetal birth weight and retarded development of the fetal kidney) and premature delivery. There are no data from controlled human pregnancy studies. Use of mitoxantrone during pregnancy is considered contraindicated. Even if they are using birth control, women with multiple sclerosis who are biologically capable of becoming pregnant should have a pregnancy test (and the results should be known) before receiving each dose of mitoxantrone. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

A brief case in which a woman successfully delivered a healthy baby girl weighing 2,960 grams by Cesarean section at 34 weeks' gestation after consolidation therapy with mitoxantrone and cytarabine for acute promyelocytic leukemia has been reported.

See references

Mitoxantrone Breastfeeding Warnings

In one case, a lactating woman, who had received mitoxantrone 6 mg/m2 once a day, a breast milk mitoxantrone concentration of 120 ng/mL was measured just after the end of the last mitoxantrone infusion. A breast milk mitoxantrone concentration of 18 ng/mL was still detectable 28 days after drug administration. These data suggest that this drug is distributed into and is slowly cleared from the mammary gland. The woman began to breast-feed her baby from 3 weeks after completion of mitoxantrone therapy. There were no abnormalities in the nursing infant during the 16 months after birth.

Mitoxantrone is excreted into human milk. In the only case report available, no adverse effects were observed in a nursing infant whose mother had received consolidation therapy for acute promyelocytic leukemia. Because of the unknown risk and the potential for serious adverse reactions in infants from mitoxantrone, breast-feeding should be discontinued before starting treatment.

See references

References for pregnancy information

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. Azuno Y, Kaku K, Fujita N, Okubo M, Kaneko T, Matsumoto N "Mitoxantrone and etoposide in breast milk." Am J Hematol 48 (1995): 131-2

References for breastfeeding information

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. Azuno Y, Kaku K, Fujita N, Okubo M, Kaneko T, Matsumoto N "Mitoxantrone and etoposide in breast milk." Am J Hematol 48 (1995): 131-2

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.